Medigene AG has announced its pipeline expansion into neoantigens with KRAS as the first target in its MDG-10xx program, a T-cell receptor engineered T cell (TCR-T) therapy being developed in combination with the company's PD1-41BB switch receptor technology.
Mesenchymal glioblastoma, a phenotype associated with poor clinical outcomes, is characterized by the expression of CD44 and chitinase 3-like protein 1 (CHI3L1) in mesenchymal glioma stem cells (GSCs). CHI3L1 has been implicated in several oncogenic pathways driving mesenchymal differentiation. However, the role of CHI3L1 as a paracrine modulator of GSC states, as well as the transcriptional regulatory network induced by CHI3L1 in GSCs, remains unknown.
Intron Biotechnology Inc. has announced the identification of lysogenic bacteriophages prophage and jamphage in the pancreatic cancer-related microbiome. This identification was achieved as part of the ongoing Phageriarus development project that is focused on acquiring bacteriophage-derived proteins that can serve as immune regulators, with the ultimate goal of developing phage-based immunotherapeutics for immune disorders and cancer.
Researchers from Healios K.K. presented preclinical data for HLCN-061, a novel gene-engineered human induced pluripotent stem cell (iPSC)-derived NK cell product being developed for the treatment of solid tumors.
Nectin cell adhesion molecule 4 (Nectin-4) overexpression in different tumors correlates with cancer progression and poor prognosis in many human malignancies. The first Nectin-4-targeting antibody, enfortumab vedotin (EV), has limited efficacy and frequent adverse effects in several solid tumors. Researchers at Mabwell (Shanghai) Bioscience Co. Ltd. and colleagues have now reported on the generation and characterization of 9MW-2821, an antibody-drug conjugate consisting of an antibody targeting Nectin-4 conjugated to monomethyl auristatin E (MMAE).
Evaxion Biotech A/S has unveiled the technology behind its proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.
Bioray Pharmaceutical Co. Ltd.’s IND application for BRY-812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration (NMPA).
RSS
